PMID: 11332148May 3, 2001Paper

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Diana CrivellariInternational Breast Cancer Study Group

Abstract

Clinically overt central nervous system (CNS) involvement occurs in 10%-15% of patients with advanced breast cancer. The International Breast Cancer Study Group (IBCSG) conducted a dose-finding phase I trial of epirubicin (E) and docetaxel (D) as first-line therapy in advanced breast cancer patients. The study was expanded into a phase II at the recommended doses of E 90 mg/m2 and D 75 mg/m2 every three weeks. From July 1996 to May 1998, a total of 92 patients (median age 50 years) entered the two studies. Twenty-eight out of ninety-two patients treated with the combination of E and D (30%) developed CNS metastases (95% confidence limits, 26%-35%), which were cerebral in twenty-five patients, leptomeningeal in two, and both in one. Of these 28 patients, 19 (68%) had an objective response. Median time for the development of CNS metastases from the start of chemotherapy was 15 months (range 5-42), if excluding the 6 patients presenting CNS progression within 3 months from start of treatment. It is notable that 11 patients (39%) had progression in the CNS only. Median survival from appearance of brain metastases in the whole group was only three months (range 1-22). C-erbB-2 overexpression was found in 14 out of 16 patients (87%) ...Continue Reading

Citations

Apr 23, 2004·Current Neurology and Neuroscience Reports·Alexis Demopoulos
Nov 15, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zsolt GabosBassam Abdulkarim
Nov 8, 2007·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Shunsuke TsukamotoTakayuki Kinoshita
Mar 30, 2010·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Oct 17, 2014·Japanese Journal of Clinical Oncology·Naoki NiikuraHiroji Iwata
Oct 31, 2019·Journal of Experimental & Clinical Cancer Research : CR·Simon BernatzMichel Mittelbronn
Oct 24, 2002·Anti-cancer Drugs·E SalminenE Ekholm
Dec 21, 2004·Breast Cancer Research and Treatment·Lisa A CareyMark L Graham
Jun 10, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Lalit KumarRajveer Singh
Oct 11, 2005·Journal of Neuro-oncology·Sophie TaillibertJean-Yves Delattre
Jan 9, 2009·Breast Cancer Research and Treatment·Renata DuchnowskaCezary Szczylik
Jul 22, 2010·Expert Review of Anticancer Therapy·Herwig Strik, Peter Prömmel
Oct 13, 2011·Journal of Neuro-oncology·Orazio CaffoEnzo Galligioni
Dec 3, 2011·Current Oncology Reports·Joseph A Bovi, Julia White
Aug 6, 2013·International Journal of Cancer. Journal International Du Cancer·Sébastien SerresNicola R Sibson
Aug 18, 2012·Breast Cancer Research : BCR·Renata DuchnowskaUNKNOWN Polish Brain Metastasis Consortium
Jan 1, 2008·Clinical Medicine. Oncology·Sanna GNolè F
Nov 28, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M J Gil-GilS Villà
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Jul 12, 2017·Journal of breast cancer·Shoko Merrit YamadaYasuhisa Baba
Jun 21, 2018·International Journal of Cancer. Journal International Du Cancer·Sherise D FergusonAmy B Heimberger
Dec 13, 2002·American Journal of Clinical Oncology·Hüseyin Abali, Ismail Celik
Jun 10, 2004·Current Opinion in Oncology·M J van den Bent
Jun 17, 2005·Expert Opinion on Pharmacotherapy·George Pentheroudakis, Nicholas Pavlidis
Jul 23, 2004·Anti-cancer Drugs·Albert J ten TijeAlex Sparreboom
Jul 21, 2009·Journal of Neuro-oncology·Corinne RenierIrene Wapnir
Mar 23, 2011·Medical Molecular Morphology·Mu-min ShaoGary M Tse
Jan 20, 2011·Journal of Experimental & Clinical Cancer Research : CR·Alessandra FabiCarmine M Carapella
Jun 19, 2013·Clinical & Experimental Metastasis·A M MinisiniF Puglisi
May 5, 2020·Neuro-oncology Advances·Raj SinghNicholas G Zaorsky
Jun 2, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jochen GaedckeHans H Kreipe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.